MEDIFAST INC (MED) Next Earnings Date & Expected ±6.8% Move

Per the Roarable RQD rating, MED scores 50 out of 100 for a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -10.2% and an FCF yield of 0.91%. Negative return on invested capital means the business is currently not earning back its capital base, and a sub-1% FCF yield indicates limited free cash generation relative to the market value.
• Whale / 13F Flow: 12 / 20. Per the Roarable RQD rating, the pillar reflects institutional accumulation and options positioning. No holder-level detail is included in the source data, so the drivers of this score cannot be independently traced here.
• Insider Conviction: 5 / 20. Per the Roarable RQD rating, this is the weakest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-side conviction; the underlying trade-level records are not included in the source data.
• Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, the pillar cites a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves, without a defensive or aggressive tilt.
• Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, the pillar reflects Altman Z 4.71, Piotroski F 5/9, and Debt/Equity 0.5. These metrics point to a balance sheet that is more stable than the earnings trajectory alone would suggest.

For a prospective investor evaluating the stock today, the composite picture is one of weak profitability and cash generation offset in part by a relatively sound balance-sheet profile. The upside drivers the data supports are the forensic balance sheet and the institutional-flow pillar; the headwinds are negative ROIC, a thin FCF yield, and weak insider conviction. Valuation tradeoffs cannot be assessed precisely because P/E and EV/EBITDA are not available in source data. The rating is a descriptive summary of the data provided and is not a recommendation.

Per the SEC financials, revenue declined from $1072.1M in FY 2023 to $385.8M in FY 2025, and the company moved from positive operating income in FY 2023 and FY 2024 to an operating loss of $-14.2M in FY 2025. Per the market data, operating margin is -3.7%, net margin is -4.9%, and ROIC is -10.2%. Per the Roarable RQD rating, the Altman Z-Score is 4.71 and the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. Reported cash was $89.3M at FY 2025. Debt is not available in source data for any period.

Per the recent news and catalysts feed, six items relate to MED:

• An item labeled "Why Medifast (MED) stock is trading up today" from Yahoo Finance (YELLOW, MARKET WIRE).
• An item on whether Medifast's client retention can support revenue stabilization from TradingView (YELLOW, MARKET WIRE).
• A Seeking Alpha item expressing concerns about the company's playbook (YELLOW, MARKET WIRE).
• A Yahoo Finance item reporting a Q3 loss while topping revenue estimates (RED, RISK WATCH).
• A MarketBeat item noting an expected quarterly earnings release on Monday (YELLOW, MARKET WIRE).
• A Stock Titan item reporting the number of actively earning coaches fell 47.7% to 10,200 (YELLOW, MARKET WIRE).

The only item flagged RISK WATCH is the Q3 loss report. The butterfly supply-chain graph contains no links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector context available is the classification as Consumer Staples / Packaged Foods. An investor should watch for the coach-count decline and client-retention commentary in the news feed as potential indicators of demand conditions, but the source data does not establish any linkage to other companies.

• What are the company's P/E (TTM), forward P/E, and EV/EBITDA, and how do they compare with peers?
• What drove the revenue decline from $1072.1M in FY 2023 to $385.8M in FY 2025, and is the trend continuing into the current period?
• What is the company's debt position by period, given that debt is listed as N/A throughout the financials?
• What are the specific insider and institutional trades behind the Insider Conviction and Whale/13F Flow pillar scores?
• What did the Q3 loss report disclose about operating drivers, and what does the FY 2025 cash balance imply about funding runway?